reference/32297339

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32297339

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	325
issn	0950-9232 1476-5594
issueIdentifier	3
pageRange	316-325
publicationName	Oncogene
startingPage	316
bibliographicCitation	Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 2014 Jan 16;33(3):316–25. doi: 10.1038/onc.2012.594. PMID: 23318440.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_193edf08be2cfee10c7385b701bed8f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7392b583eeb860e909e7c73e0235eb6a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_714b538034ec4330624899a1f4fce0ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2e61e12c46c2a6619df53575616f9859 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6c7faa6c925bb0f54ee98ec7b820aed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_72c27c48eb67cff0f8bab7b2f9f6ed7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c20d79800cbe26bba268f36a305dc5f8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56618816367da6f1af8a7f2f8c41adb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_986d6d2f1c9e9d05d7e4a4bec452f45b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e04caac67192ba93e1252dd309acbae5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aca567ea1e1f94557d253d54e591c6af http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21fb770d80974fe268533ecb85be2cb4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_396b8e4983a257ae32af688058292499
date	2013-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/23318440 https://doi.org/10.1038/onc.2012.594
isPartOf	https://portal.issn.org/resource/ISSN/1476-5594 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6325 https://portal.issn.org/resource/ISSN/0950-9232
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
discusses	http://id.nlm.nih.gov/mesh/M0481564 http://id.nlm.nih.gov/mesh/M000649677 http://id.nlm.nih.gov/mesh/M0150739 http://id.nlm.nih.gov/mesh/M0479831 http://id.nlm.nih.gov/mesh/M0006099 http://id.nlm.nih.gov/mesh/M0021267 http://id.nlm.nih.gov/mesh/M0543055 http://id.nlm.nih.gov/mesh/M0525738 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0465491 http://id.nlm.nih.gov/mesh/M0011208
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112 http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6def9ba73d737095d7c10e997bbe18be http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3b988930bf581303c87c5255963c9a15 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8561 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a95421c679462609c9ef4e68005e1dcc http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_98035231fcaee69b50d4e6e928e41169 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17755052 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216326 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1ab93dab864d412d37c9dcb9c25f8a38 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_78edc8e186d4ca89a5d99640d0f188ad http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.4.2.30

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID53786789 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID53788392 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5290 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5291 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID376229524 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID160778578

Total number of triples: 65.